Small Molecules
28 September 2013
Marketing Authorisation Application for olaparib accepted by European Medicines Agency27 September 2013
Nektar Announces Preliminary Topline Results from Phase 2 Efficacy Study for NKTR-181 in Chronic Pain Patients with Osteoarthritis of the Knee27 September 2013
Marketing Authorisation Application for naloxegol accepted by European Medicines Agency27 September 2013
Cornerstone Pharmaceuticals Initiates Phase II Clinical Trial of CPI-613 for the Treatment of Myelodysplastic Syndrome26 September 2013
Verastem Initiates Phase 2 Trial of Defactinib in Lung Cancer26 September 2013
ProMetic’s Lead Drug Candidate, PBI-4050, Enters Clinical Program26 September 2013
Pharmaceutical company Dompé launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation26 September 2013
European Commission Approves Gilead Sciences’ Tybost™, a New Boosting Agent for HIV Therapy25 September 2013
Merck Receives Complete Response Letter for Investigational Medicine Sugammadex Sodium Injection25 September 2013
Acorda Therapeutics Announces Initiation of Phase 2 Trial of Treatment for Spinal Cord Injury25 September 2013
KemPharm’s KP201 Demonstrates Bioequivalence Compared to Norco® in Key Pivotal Clinical Study25 September 2013
Sunesis Pharmaceuticals Completes Enrollment in Phase 3 VALOR Trial of Vosaroxin in AML25 September 2013
GIOTRIF® (afatinib)* approved in Europe for patients with EGFR mutation positive lung cancer25 September 2013
Infinity Reports Topline Data from Phase 2 Study of Retaspimycin Hydrochloride, Its Hsp90 Inhibitor, in Patients with Non-Small Cell Lung Cancer24 September 2013
Neurovance Announces FDA Acceptance of IND Application For EB-1020 SR and Initiates Phase 2a Study in Adult ADHD24 September 2013
Edison Pharmaceuticals Announces Initiation of NIH-Sponsored EPI-743 Clinical Trial with NIH Undiagnosed Diseases Program Patients24 September 2013
Purdue Pharma L.P. Receives FDA Approval For 15 mcg/hour Dosage Strength Of Butrans® (Buprenorphine) Transdermal System CIII24 September 2013
BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease24 September 2013
Agios Pharmaceuticals Enrolls First Patient in Phase 1 Study of AG-221 in Advanced Hematologic Malignancies with an IDH2 Mutation20 September 2013
Otsuka and Lundbeck Receive Positive CHMP Opinion in Europe for Abilify MaintenaTM, a Once-Monthly Injectable for Schizophrenia20 September 2013
Phosphagenics Begins Oxymorphone Pain Relief Patch Multi-dose TrialNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports